JP2005517403A5 - - Google Patents

Info

Publication number

JP2005517403A5

JP2005517403A5 JP2003568053A JP2003568053A JP2005517403A5 JP 2005517403 A5 JP2005517403 A5 JP 2005517403A5 JP 2003568053 A JP2003568053 A JP 2003568053A JP 2003568053 A JP2003568053 A JP 2003568053A JP 2005517403 A5 JP2005517403 A5 JP 2005517403A5

Authority

JP

Japan

Prior art keywords

bladder

human

epithelial cells

human fetal

derived

Prior art date

2003-02-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 210000003932 urinary bladder Anatomy 0.000 claims 79
• 210000002919 epithelial cell Anatomy 0.000 claims 74
• 230000001605 fetal effect Effects 0.000 claims 62
• 238000000034 method Methods 0.000 claims 30
• 210000001519 tissue Anatomy 0.000 claims 13
• 210000004027 cell Anatomy 0.000 claims 8
• 239000002609 medium Substances 0.000 claims 6
• 235000015097 nutrients Nutrition 0.000 claims 6
• 210000000064 prostate epithelial cell Anatomy 0.000 claims 6
• 210000000981 epithelium Anatomy 0.000 claims 5
• 210000002307 prostate Anatomy 0.000 claims 5
• 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims 4
• 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims 4
• 102000048238 Neuregulin-1 Human genes 0.000 claims 4
• 108090000556 Neuregulin-1 Proteins 0.000 claims 4
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 4
• 238000004166 bioassay Methods 0.000 claims 4
• 230000004069 differentiation Effects 0.000 claims 4
• 229940079593 drug Drugs 0.000 claims 4
• 239000003814 drug Substances 0.000 claims 4
• 210000003754 fetus Anatomy 0.000 claims 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
• 239000002356 single layer Substances 0.000 claims 4
• 238000013334 tissue model Methods 0.000 claims 4
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 4
• 102000007469 Actins Human genes 0.000 claims 3
• 108010085238 Actins Proteins 0.000 claims 3
• 108091005461 Nucleic proteins Proteins 0.000 claims 3
• 210000005068 bladder tissue Anatomy 0.000 claims 3
• 230000028993 immune response Effects 0.000 claims 3
• 108020004999 messenger RNA Proteins 0.000 claims 3
• 108020004707 nucleic acids Proteins 0.000 claims 3
• 102000039446 nucleic acids Human genes 0.000 claims 3
• 150000007523 nucleic acids Chemical class 0.000 claims 3
• 108090000623 proteins and genes Proteins 0.000 claims 3
• 102000004169 proteins and genes Human genes 0.000 claims 3
• 210000002966 serum Anatomy 0.000 claims 3
• 108010039627 Aprotinin Proteins 0.000 claims 2
• 102000004877 Insulin Human genes 0.000 claims 2
• 108090001061 Insulin Proteins 0.000 claims 2
• 102000004338 Transferrin Human genes 0.000 claims 2
• 108090000901 Transferrin Proteins 0.000 claims 2
• 229940087168 alpha tocopherol Drugs 0.000 claims 2
• 229960004405 aprotinin Drugs 0.000 claims 2
• 238000011161 development Methods 0.000 claims 2
• 238000000338 in vitro Methods 0.000 claims 2
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 2
• 229940125396 insulin Drugs 0.000 claims 2
• 230000005012 migration Effects 0.000 claims 2
• 238000013508 migration Methods 0.000 claims 2
• 238000011170 pharmaceutical development Methods 0.000 claims 2
• 229960003387 progesterone Drugs 0.000 claims 2
• 239000000186 progesterone Substances 0.000 claims 2
• 229960000984 tocofersolan Drugs 0.000 claims 2
• 239000012581 transferrin Substances 0.000 claims 2
• 239000002076 α-tocopherol Substances 0.000 claims 2
• 235000004835 α-tocopherol Nutrition 0.000 claims 2
• 230000002163 immunogen Effects 0.000 claims 1
• 239000003147 molecular marker Substances 0.000 claims 1
• 239000012679 serum free medium Substances 0.000 claims 1